RENVELA 2.4g price in UAE

Overview

Welcome to Dwaey, specifically on RENVELA 2.4g Suspension/Powder for page.
This medicine contains an important and useful components, as it consists of Sevelamer carbonate.
RENVELA 2.4g is available in the market in concentration 2.4g/Sachet and in the form of Suspension/Powder for.

GENZYME EUROPE B.V. is the producer of RENVELA 2.4g and it is imported from NETHERLANDS, The most popular alternatives of RENVELA 2.4g are listed downward .

Mode Of Action

Sevelamer, a polymeric compound, acts by binding to phosphate molecules in the gut, limiting its absorption and thus lowering serum phosphate levels w/o altering Ca, Al, or bicarbonate levels.

Indication

Hyperphosphataemia

Precaution

Patients w/ dysphagia, swallowing disorders, severe GI motility disorders, active inflammatory bowel disease or major GI tract surgery. Pregnancy and lactation. Monitoring Parameters Monitor serum levels of phosphate, Ca, Cl and bicarbonate. Vitamin supplementation due to reduction in vit D, E, K and folic acid absorption. Monitor for signs and symptoms of peritonitis in patients undergoing peritoneal dialysis. Lactation: Not absorbed systemically; not excreted in breast milk

Side Effects

>10% Vomiting (22%)
Nausea (20%)
Diarrhea (19%)
Dyspepsia (16%)
Nasopharyngitis (14%)
Limb pain (13%)
Pruritus (13%)
Arthralgia (12%)
Bronchitis (11%)
Dyspnea (10%)
Hypertension (10%) 1-10% Abdominal pain (9%)
Constipation (8%)
Flatulence (8%)
Peritonitis (during peritoneal dialysis: 8%)
Hypercalcemia (5-7%) Frequency Not Defined Back pain
Cough
Headache
Pyrexia
Upper respiratory infection
Pruritus
Rash
Intestinal perforation
Fecal impaction
Intestinal obstruction.

Contra indication

Hypophosphatemia or bowel obstruction.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May decrease absorption of ciprofloxacin, ciclosporin, mycophenolate, tacrolimus and levothyroxine. Sevelamer should be given 3 hr before or 1 hr after taking other drugs to minimise potential pharmacokinetic interaction.